Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: COVID-19 Drugs  Jul 22, 2020  3 years, 8 months, 4 weeks, 1 hour, 38 minutes ago

COVID-19 Drugs: Heron Therapeutics Starts Phase 2 Clinical Study of CINVANTI (Aprepitant) For Prevention And Treatment Of Lung Injury In COVID-19 Patients

COVID-19 Drugs: Heron Therapeutics Starts Phase 2 Clinical Study of CINVANTI (Aprepitant) For Prevention And Treatment Of Lung Injury In COVID-19 Patients
Source: COVID-19 Drugs  Jul 22, 2020  3 years, 8 months, 4 weeks, 1 hour, 38 minutes ago
COVID-19 Drugs: Heron Therapeutics, Inc, a commercial-stage biotechnology company announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with COVID-19.


 
The research study initiation follows clearance from the U.S. FDA of Heron's Investigational New Drug application for CINVANTI for the treatment of COVID-19.
 
The pharmaceutical preparation: CINVANTI is an intravenous formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist (RA) approved for use for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Substance P, and its receptor NK1, is distributed throughout the body in the cells of many tissues and organs, including the lungs. COVID-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated wit